pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2019-29-4-499-507pulmo-1204Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYИнгаляционная терапия у детей: новые возможностиInhalation therapy in children: new opportunitiesЛокшинаЭ. Э.LokshinaЕ. Е.

Локшина Эвелина Эдуардовна – кандидат медицинских наук, доцент кафедры педиатрии

127473, Москва, ул. Делегатская, 20 / 1

Evelina E. Lokshina, Candidate of Medicine, Associate Professor, Department of Pediatrics

ul. Delegatskaya 20, build. 1, Moscow, 127473

elokshina@yandex.ruЗайцеваО. В.ZaytsevaО. V.

Зайцева Ольга Витальевна – доктор медицинских наук, профессор, заведующая кафедрой педиатрии

127473, Москва, ул. Делегатская, 20 / 1

Ol’ga V. Zaytseva, Doctor of Medicine, Professor, Head of Department of Pediatrics

ul. Delegatskaya 20, build. 1, Moscow, 127473

olga6505963@yandex.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияA.I.Evdokimov Moscow State University of Medicine and Dentistry, Healthcare Ministry of RussiaRussian Federation201924102019294499507Copyright © Локшина Э.Э., Зайцева О.В., 20192019Локшина Э.Э., Зайцева О.В.Lokshina Е.Е., Zaytseva О.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1204

Ингаляционная терапия широко используется при комплексном лечении острых респираторных инфекций и бронхиальной астмы у детей, обеспечивая быструю доставку препарата в дыхательные пути (ДП). Успехи в лечении заболеваний органов дыхания у детей определяются не только правильным выбором лекарственного средства, режимом дозирования, но и способом доставки препарата. Выбор системы доставки у детей во многом зависит от возраста и способности ребенка выполнять инструкции, связанные с техникой ингаляции. При неверно выполненной ингаляции лекарственное вещество в ДП распределяется неправильно, необоснованно увеличивается объем терапии, возрастает не только число побочных эффектов, но и общая стоимость лечения. На современном рынке существует множество разнообразных систем доставки лекарственных средств – дозированные аэрозольные ингаляторы (ДАИ), ДАИ со спейсером и лицевой маской, дозированные порошковые ингаляторы, небулайзеры. Наиболее оптимальной системой доставки лекарственных средств в ДП у детей любого возраста является небулайзер. В статье изложены преимущества и недостатки разных систем доставки, приводится описание современных небулайзеров, используемых при заболеваниях верхних и нижних отделов ДП, в т. ч. возможности комбинированного небулайзера DuoBaby с назальным аспиратором («два-в-одном»).

 

Inhalation therapy is widely used for treatment of acute respiratory infections and asthma in children, and provides more rapid drug delivery in the airways. Treatment success in children with respiratory diseases is defined not only by an adequate choice of the drug and the dosage regimen, but also by inhalation drug delivery system. The choice of drug delivery device in children depends on the child's age and ability to carry out instructions related to the inhalation technique. Incorrect inhalation technique is associated with inappropriate distribution of the drug in the respiratory tract and an unreasonable increase in the volume of therapy, risk of adverse effects, and the total cost of the treatment. Currently, a great number of various drug delivery systems are commercially available, such as a pressurised metered dose inhaler (MDI), a MDI with spacer and facemask, a dry powder inhaler, and a nebulizer. The most optimal inhalation drug delivery device for children is a nebulizer. In this article, the authors discussed benefits and limitations of various drug delivery systems and modern nebulizers used for treatment of the upper and the lower airways including DuoBaby nebulizer 2-in-1 with a nasal aspirator.

 

детиингаляционная терапиянебулайзерназальный аспираторострые респираторные инфекциибронхиальная обструкциябронхиальная астма.childreninhalation therapynebulizernasal aspiratorrespiratory infectionswheezingasthmaReferencesЛокшина Э.Э., Зайцева О.В., Зайцева С.В. Ингаляционная терапия респираторных заболеваний у детей. Атмосфера. Пульмонология и аллергология. 2012; (4): 41–45.Lokshina E.E., Zaytseva O.V., Zaytseva S.V. [Inhalation therapy of respiratory diseases in children]. Atmosfera. Pul'monologiya i allergologiya. 2012; (4): 41–45 (in Russian).Захарова И.Н., Касьянова А.Н., Климов Л.Я. и др. Микробиом респираторного тракта: что известно сегодня? Педиатрия (Прил. к журн. Consilium Medicum). 2018; 4: 10–17. DOI: 10.26442/24138460.2018.4.180129.Zakharova I.N., Kas'yanova A.N., Klimov L.Ya. et al. [Respiratory tract microbiome: what is known today?]. Pediatriya (Suppl. Consilium Medicum). 2018; (4): 10–17. DOI: 10.26442/24138460.2018.4.180129 (in Russian).Dickson R.P., Erb-Downward J.R., Freeman C.M. et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann. Am. Thorac. Soc. 2015; 12 (6): 821–830. DOI: 10.1513/AnnalsATS.201501-029OC.Dickson R.P., Erb-Downward J.R., Freeman C.M. et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann. Am. Thorac. Soc. 2015; 12 (6): 821–830. DOI: 10.1513/AnnalsATS.201501-029OC.Bassis C.M., Erb-Downward J.R., Dickson R.P. et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015; 6 (2): e00037. DOI: 10.1128/mBio.00037-15.Bassis C.M., Erb-Downward J.R., Dickson R.P. et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015; 6 (2): e00037. DOI: 10.1128/mBio.00037-15.Charlson E.S., Bittinger K, Haas A.R. et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am. J. Respir. Crit. Care Med. 2011; 184 (8): 957–963. DOI: 10.1164/rccm.201104-0655OC.Charlson E.S., Bittinger K, Haas A.R. et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am. J. Respir. Crit. Care Med. 2011; 184 (8): 957–963. DOI: 10.1164/rccm.201104-0655OC.Prevaes S.M., de Winter-de Groot K.M., Janssens H.M. et al. Development of the nasopharyngeal microbiota in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2016; 193 (5): 504–515. DOI: 10.1164/rccm.201509-1759OC.Prevaes S.M., de Winter-de Groot K.M., Janssens H.M. et al. Development of the nasopharyngeal microbiota in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2016; 193 (5): 504–515. DOI: 10.1164/rccm.201509-1759OC.Hoen A.G., Li J, Moulton L.A. et al. Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J. Pediatr. 2015; 167 (1): 138–147. e1–3. DOI: 10.1016/j.jpeds.2015.02.049.Hoen A.G., Li J, Moulton L.A. et al. Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J. Pediatr. 2015; 167 (1): 138–147. e1–3. DOI: 10.1016/j.jpeds.2015.02.049.Зайцева С.В., Снитко С.Ю., Зайцева О.В., Локшина Э.Э. Терапия острого обструктивного синдрома у детей с острыми респираторными заболеваниями. Лечащий врач. 2013; (11): 50–55.Zaytseva S.V., Snitko S.Yu., Zaytseva O.V., Lokshina E.E. [Treatment of acute bronchial obstruction in children with acute respiratory diseases]. Lechashchiy vrach. 2013; (11): 50–55 (in Russian).Зайцева О.В. Острые обструктивные состояния дыхательных путей у детей Атмосфера. Пульмонология и аллергология. 2005; (2): 6–10.Zaytseva O.V. [Acute airway obstruction in children]. Atmosfera. Pul'monologiya i allergologiya. 2005; (2): 6–10 (in Russian).Зайцева О.В. Бронхообструктивный синдром у детей. Педиатрия. 2005; 84 (4): 94–104.Zaytseva O.V. [Bronchial obstruction in children]. Pediatriya. 2005; 84 (4): 94–104 (in Russian).Симонова О.И., Горинова Ю.В., Алексеева А.А., Томилова А.Ю. Бронхообструктивный синдром у детей: новое решение старой проблемы. Вопросы современной педиатрии. 2015; 14 (2): 276–280.Simonova O.I., Gorinova Yu.V., Alekseeva A.A., Tomilova A.Yu. [Bronchial obstruction in children: a new solution to an old problem]. Voprosy sovremennoy pediatrii. 2015; 14 (2): 276–280 (in Russian).Brand P.L., Caudri D., Eber E. et al. Classification and pharmacological treatment of preschool wheezing: changes since 2008. Eur. Respir. J. 2014; 43 (4): 1172–1177. DOI: 10.1183/09031936.00199913.Brand P.L., Caudri D., Eber E. et al. Classification and pharmacological treatment of preschool wheezing: changes since 2008. Eur. Respir. J. 2014; 43 (4): 1172–1177. DOI: 10.1183/09031936.00199913.Muers M.F. Overview of nebulizer treatment. Thorax. 1997; 52 (Suppl. 2): S25–30. DOI: 10.1136/thx.52.2008.s25.Muers M.F. Overview of nebulizer treatment. Thorax. 1997; 52 (Suppl. 2): S25–30. DOI: 10.1136/thx.52.2008.s25.Зайцева О.В., Зайцева С.В. Небулайзеры в лечении заболеваний органов дыхания у детей. Русский медицинский журнал. 2013; 21 (25): 1228–1232.Zaytseva O.V., Zaytseva S.V. [Nebulizers for treatment of respiratory diseases in children]. Russkiy meditsinskiy zhurnal. 2013; 21 (25): 1228–1232 (in Russian).Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд., перераб. и доп. М.: Оригинал-макет; 2017.Bronchial Asthma in Children. A Strategy of Treatment and Prevention. A National Programme. 5th Revised and Enlarged Edition. Moscow: Original-maket; 2017 (in Russian).Downs K.E. et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000; 117 (2): 542–550. DOI: 10.1378/chest.117.2.542.Downs K.E. et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000; 117 (2): 542–550. DOI: 10.1378/chest.117.2.542.Зайцева С.В., Лаврентьев А.В., Зайцева. О.В. Аэрозольтерапия в лечении бронхиальной астмы у детей. Лечащий врач. 2000; (3): 28–31.Zaytseva S.V., Lavrent'ev A.V., Zaytseva. O.V. [Aerosolized therapy of bronchial asthma in children]. Lechashchiy vrach. 2000; (3): 28–31 (in Russian).Жестков А.В., Светлова Г.Н., Косов А.И. Короткодействующие b2-агонисты: механизмы действия и фармакотерапия бронхиальной астмы и хронической обструктивной болезни легких. Consilium Medicum. 2008; 10 (3): 99–103.Zhestkov A.V., Svetlova G.N., Kosov A.I. [Short-acting b2-agonists: mechanisms of action and pharmacological therapy of asthma and chronic obstructive pulmonary disease]. Consilium Medicum. 2008; 10 (3): 99–103 (in Russian).Фисенко В.П., Чичкова Н.В. Современная лекарственная терапия бронхиальной астмы. Врач. 2006; (1): 56–60.Fisenko V.P., Chichkova N.V. [Current pharmacological therapy of bronchial asthma]. Vrach. 2006; (1): 56–60 (in Russian).Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. 2002; 19 (2): 246–251. DOI: 10.1183/09031936.02.00218402.Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. 2002; 19 (2): 246–251. DOI: 10.1183/09031936.02.00218402.Schueepp K.G., Devadason S.G., Roller C. et al. Aerosol delivery of nebulised budesonide in young children with asthma. Respir. Med. 2009; 103 (11): 1738–1745. DOI: 10.1016/j.rmed.2009.04.029.Schueepp K.G., Devadason S.G., Roller C. et al. Aerosol delivery of nebulised budesonide in young children with asthma. Respir. Med. 2009; 103 (11): 1738–1745. DOI: 10.1016/j.rmed.2009.04.029.Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1407. DOI: 10.1183/09031936.00166410.Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1407. DOI: 10.1183/09031936.00166410.Авдеев С.Н. Новое поколение небулайзеров. Медицинский алфавит. 2010; 1–2 (8): 30–34.Avdeev S.N. [A new generation of nebulizers]. Meditsinskiy alfavit. 2010; 1–2 (8): 30–34 (in Russian).Chonmaitree T., Revai K., Grady J.J. et al. Viral upper respiratory tract infection and otitis media complication in young children. Clin. Infect. Dis. 2008; 46 (6): 815–823. DOI: 10.1086/528685.Chonmaitree T., Revai K., Grady J.J. et al. Viral upper respiratory tract infection and otitis media complication in young children. Clin. Infect. Dis. 2008; 46 (6): 815–823. DOI: 10.1086/528685.Revai K., Dobbs L.A., Nair S. et al. Incidence of acute otitis media and sinusitis complicating upper respiratory tract infection: the effect of age. Pediatrics. 2007; 119 (6): e1408–1412. DOI: 10.1542/peds.2006-2881.Revai K., Dobbs L.A., Nair S. et al. Incidence of acute otitis media and sinusitis complicating upper respiratory tract infection: the effect of age. Pediatrics. 2007; 119 (6): e1408–1412. DOI: 10.1542/peds.2006-2881.Licari A., Brambilla I., De Filippo M. et al. The role of upper airway pathology as a co-morbidity in severe asthma. Exp. Rev. Respir. Med. 2017; 11 (11): 855–865. DOI: 10.1080/17476348.2017.1381564.Licari A., Brambilla I., De Filippo M. et al. The role of upper airway pathology as a co-morbidity in severe asthma. Exp. Rev. Respir. Med. 2017; 11 (11): 855–865. DOI: 10.1080/17476348.2017.1381564.Kohli N., DeCarlo D., Goldstein N.A., Silverman J. Asthma outcomes after adenotonsillectomy: a systematic review. Int. J. Pediatr. Otorhinolaryngol. 2016; 90: 107–112. DOI: 10.1016/j.ijporl.2016.08.030.Kohli N., DeCarlo D., Goldstein N.A., Silverman J. Asthma outcomes after adenotonsillectomy: a systematic review. Int. J. Pediatr. Otorhinolaryngol. 2016; 90: 107–112. DOI: 10.1016/j.ijporl.2016.08.030.Compalati E., Ridolo E., Passalacqua G. et al. The link between allergic rhinitis and asthma: the united airways disease. Exp. Rev. Clin. Immunol. 2010; 6 (3): 413–423. DOI: 10.1586/eci.10.15.Compalati E., Ridolo E., Passalacqua G. et al. The link between allergic rhinitis and asthma: the united airways disease. Exp. Rev. Clin. Immunol. 2010; 6 (3): 413–423. DOI: 10.1586/eci.10.15.Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 (Suppl. 86): 8–160. DOI: 10.1111/j.1398-9995.2007.01620.x.Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 (Suppl. 86): 8–160. DOI: 10.1111/j.1398-9995.2007.01620.x.Bousquet J., Addis A., Adcock I. et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur. Respir. J. 2014; 44 (2): 304–323. DOI: 10.1183/09031936.00014614.Bousquet J., Addis A., Adcock I. et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur. Respir. J. 2014; 44 (2): 304–323. DOI: 10.1183/09031936.00014614.Giavina-Bianchi P., Aun M.V., Takejima P. et al. United airway disease: current perspectives. J. Asthma Allergy. 2016; 9: 93–100. DOI: 10.2147/JAA.S81541.Giavina-Bianchi P., Aun M.V., Takejima P. et al. United airway disease: current perspectives. J. Asthma Allergy. 2016; 9: 93–100. DOI: 10.2147/JAA.S81541.Chirico G., Quartarone G., Mallefet P. Nasal congestion in infants and children: a literature review on efficacy and safety of non-pharmacological treatments. Minerva Pediatr. 2014; 66 (6): 549–557.Chirico G., Quartarone G., Mallefet P. Nasal congestion in infants and children: a literature review on efficacy and safety of non-pharmacological treatments. Minerva Pediatr. 2014; 66 (6): 549–557.Verger T.J., Verger E.E. Respiratory syncytial virus bronchiolitis in children. Crit. Care Nurs. Clin. North Am. 2012; 24 (4): 555–572. DOI: 10.1016/j.ccell.2012.07.008.Verger T.J., Verger E.E. Respiratory syncytial virus bronchiolitis in children. Crit. Care Nurs. Clin. North Am. 2012; 24 (4): 555–572. DOI: 10.1016/j.ccell.2012.07.008.Roberts G., Xatzipsalti M., Borrego L.M. et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013; 68 (9): 1102–1116. DOI: 10.1111/all.12235.Roberts G., Xatzipsalti M., Borrego L.M. et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013; 68 (9): 1102–1116. DOI: 10.1111/all.12235.Casati M., Picca M., Marinello R., Quartarone G. Safety of use, efficacy and degree of parental satisfaction with the nasal aspirator Narhinel in the treatment of nasal congestion in babies. Minerva Pediatr. 2007; 59 (4): 315–325.Casati M., Picca M., Marinello R., Quartarone G. Safety of use, efficacy and degree of parental satisfaction with the nasal aspirator Narhinel in the treatment of nasal congestion in babies. Minerva Pediatr. 2007; 59 (4): 315–325.Montanari G., Ceschin F., Masotti S. et al. Observational study on the performance of the Narhinel method (nasal aspirator and physiological saline solution) versus physiological saline solution in the prevention of recurrences of viral rhinitis and associated complications of the upper respiratory tract infections (URTI), with a special focus on acute rhinosinusitis and acute otitis of the middle ear. Minerva Pediatr. 2010; 62 (1): 9–21.Montanari G., Ceschin F., Masotti S. et al. Observational study on the performance of the Narhinel method (nasal aspirator and physiological saline solution) versus physiological saline solution in the prevention of recurrences of viral rhinitis and associated complications of the upper respiratory tract infections (URTI), with a special focus on acute rhinosinusitis and acute otitis of the middle ear. Minerva Pediatr. 2010; 62 (1): 9–21.Pizzulli A., Perna S., Bennewiz A. et al. The impact of nasal aspiration with an automatic device on upper and lower respiratory symptoms in wheezing children: a pilot case-control study. Ital. J. Pediatr. 2018; 44 (1): 68. DOI: 10.1186/s13052-018-0489-6.Pizzulli A., Perna S., Bennewiz A. et al. The impact of nasal aspiration with an automatic device on upper and lower respiratory symptoms in wheezing children: a pilot case-control study. Ital. J. Pediatr. 2018; 44 (1): 68. DOI: 10.1186/s13052-018-0489-6.

The authors declare that there are no conflicts of interest present.